SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001654954-24-005065
Filing Date
2024-04-26
Accepted
2024-04-26 08:30:21
Documents
7
Period of Report
2024-06-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A tenx_def14a.htm DEF 14A 592108
2 tenx_def14aimg12.jpg GRAPHIC 688
3 tenx_def14aimg13.jpg GRAPHIC 702
4 tenx_def14aimg14.jpg GRAPHIC 132195
5 tenx_def14aimg15.jpg GRAPHIC 98150
6 tenx_def14aimg16.jpg GRAPHIC 24328
7 tenx_def14aimg17.jpg GRAPHIC 10268
  Complete submission text file 0001654954-24-005065.txt   960987
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34600 | Film No.: 24878980
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)